On Demand 2017 Which T2 Biologic is Best Suited for GINA 4-5 Non-responders? (MOC)
Price: NOW 20% OFF! $20 members, $28 non-members
You can earn up to 1.25 AMA PRA Category 1 Credits™, and up to 1.25 MOC Part II Self-Assessment credits.
There are multiple biologics that have been approved for asthma. This session explores the patient profiles that may predict a response to each agent.
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Of the AMA PRA Category 1 Credits™ listed above, the ABAI has designated a maximum of 1.25 credits as meeting the requirements for MOC Part II Self-Assessment.
The live activity was supported by an independent educational grant from GlaxoSmithKline
Medical professionals who treat patients with allergic and/or immunological conditions:
- Practicing allergist/immunologists
- Allergy/immunology Fellows-in-Training
- Physician assistants
- Nurses and advanced practice nurses
- Allied health professionals
- Primary care physicians
- Other medical professionals
Upon completion of this session, participants should be able to:
- Describe what biomarkers may be indicative of good response to treatment with anti-IgE.
- Discuss differences in outcomes of pivotal trials for the two approved anti-IL5 agents.
- Determine whether treatment failure with one biologic dictates lack of response to other agents.
- John J. Oppenheimer, MD, FACAAI
- Thomas B. Casale, MD, FACAAI
- Paul O'Byrne, MD
- Elliot Israel, MD
- 1.25 AMA PRA Category 1 Credit™
- 1.25 Attendance
- 1.25 MOC